MedPath

NeurAxon Inc

๐Ÿ‡จ๐Ÿ‡ฆCanada
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Phase 2
Completed
Conditions
Post Herpetic Neuralgia
Interventions
Drug: Placebo
First Posted Date
2012-12-13
Last Posted Date
2014-06-19
Lead Sponsor
NeurAxon Inc.
Target Recruit Count
188
Registration Number
NCT01748877
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Neurological Research Institute, Santa Monica, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

FPA Clinical Research, Kissimmee, Florida, United States

๐Ÿ‡จ๐Ÿ‡ฆ

Manna Research, Inc., Toronto, Ontario, Canada

and more 21 locations

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

Phase 2
Completed
Conditions
Migraine Without Aura
Interventions
Drug: Placebo
First Posted Date
2009-08-17
Last Posted Date
2014-07-23
Lead Sponsor
NeurAxon Inc.
Target Recruit Count
195
Registration Number
NCT00959751
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Comprehensive Neuroscience, Inc., St. Petersburg, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Elkind Headache Center, Mount Vernon, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Comprehensive NeuroScience, Inc. Atlanta, Atlanta, Georgia, United States

and more 1 locations

Study of NXN 188 for the Treatment of Migraine With Aura

Phase 2
Completed
Conditions
Migraine With Aura
Interventions
First Posted Date
2009-06-15
Last Posted Date
2014-08-11
Lead Sponsor
NeurAxon Inc.
Target Recruit Count
239
Registration Number
NCT00920686
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Research Center of Southern California, LLC, Oceanside, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

C. Philip O'Carrroll, MD, Inc., Newport Beach, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco Headache Clinic, San Francisco, California, United States

and more 13 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath